Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom

Eye (Basingstoke)

Volumn 31, Issue 12, 2017, Pages 1707-1715

  Bailey, C ^a   Chakravarthy, U ^b   Lotery, A ^c   Menon, G ^d   Talks, J ^e  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d FRIMLEY PARK HOSPITAL   (United Kingdom)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; GLUCOCORTICOID;

AGED; ARTICLE; CENTRAL SUBFIELD THICKNESS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ELECTRONIC MEDICAL RECORD; ELECTRONIC MEDICAL RECORD SYSTEM; FEMALE; FOLLOW UP; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; UNITED KINGDOM; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; CLINICAL TRIAL; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFECTS; DRUG IMPLANT; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTICENTER STUDY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY;

EID: 85029780444     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2017.125     Document Type: Article

References (22)

1. YauJW, RogersSL, KawasakiR, Lamoureux EL, Kowalski JW, Bek T et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35(3): 556-564.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102(1): 7-16.
3. Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(Suppl): 452-461.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103(12): 1796-1806.
5. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119(4): 789-801.
6. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120(10): 2013-2022.
7. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372(13): 1193-1203.
8. Dugel PU, Campbell J, Holekemp N, Kiss S, Lowenstein A, Augustin A et al. Long-term response to anti-VEGF therapy for diabetic macular edema can be predicted after 3 injections: an analysis of Protocol I data. Paper presented at the American Academy of Ophthalmology Annual Meeting; 14-17 November 2015; Las Vegas, NV, USA.
9. Danis RP, Sadda S, Li XY, Cui H, Hashad Y, Whitcup SM. Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials. Br J Ophthalmol 2016; 100(6): 796-801.
10. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119(10): 2125-2132.
11. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118(4): 626-635.
12. Boyer DS, Yoon YH, Belfort R Jr., Bandello F, Maturi RK, Augustin AJ et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121(10): 1904-1914.
13. Alimera Sciences Limited. Summary of product characteristics for ILUVIEN 190 micrograms intravitreal implant in applicator. 2012. Available from: https://www. medicines. org. uk/emc/ medicine/27636 (Accessed on June 2017).
14. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115(9): 1447-1449.
15. Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127(3): 245-251.
16. Daruich A, Matet A, Behar-Cohen F. Sustained-release steroids for the treatment of diabetic macular edema. Curr Diab Rep 2015; 15(11): 99.
17. Parrish RK, Campochiaro PA, Pearson PA, Green K, Traverso CE; FAME Study Group. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging Retina 2016; 47(5): 426-435.
18. Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Ther 2015; 4(1): 51-58.
19. Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol 2015; 9: 801-811.
20. Elaraoud I, Andreatta W, Kidess A, Bhatnagar A, TsaloumasM, Quhill F et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016; 16: 3.
21. Novartis. Summary of product characteristics for Lucentis 10mg/ml solution for injection. 2016. Available from: https://www. medicines. org. uk/emc/medicine/19409 (Accessed on June 2017).
22. Bron AM, Viswanathan AC, Thelen U, de Natale R, Ferreras A, Gundgaard J et al. International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease. Clin Ophthalmol 2010; 4: 1361-1369.